Search Videos and More
News
Dr. Mariella Filbin Receives 2026 Emerging Leader Award from The Mark Foundation
he Mark Foundation for Cancer Research has named Dr. Mariella Filbin, Research Co-Director of the Pediatric Neuro-Oncology Program at Dana-Farber Cancer Institute, the recipient of the 2026 Emerging Leader Award, recognizing her innovative work to advance treatment options for aggressive childhood brain tumors.
News
Seeing Is Believing
How Technicolor Images of Tumor Samples Are Changing Cancer Research
News
Dana-Farber Researchers Discover How Major Nuclear Protein Complexes Control Specialized Gene Regulation in Cancer and Beyond
The SWI/SNF Ig-Fold for Transcription Factor Interactions or ‘SWIFT’ domain on mSWI/SNF chromatin remodeling complexes engage proteins called transcription factors (TFs) to target specialized genes along human DNA—often cancer-promoting genes—flagging SWIFT-TF interactions as promising new therapeutic targets.
News
Dana-Farber Research News 01.01.2026
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from December 1 - 15.
Video
Jennifer Brown, MD, PhD discusses results form the ALPINE trial
Symptom-based progression-free survival (S-PFS) as a clinically relevant and patient-centric endpoint in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
Video
Austin Kim, MD discusses phase I/II study
Phase I/II study of acalabrutinib, venetoclax, and obinutuzumab in patients with relapsed/refractory and previously untreated Mantle Cell Lymphoma (MAVO)
Video
Marlise Luskin, MD, MSCE discusses results of a phase 1 trial
Venetoclax plus inotuzumab ozogramicin for relapsed and refractory ALL: Results of a phase 1 trial
Video
Maria Capilla Guerra, MD discusses rapid diagnosis of acute leukemia with integrated epigentic and genetic profiling
Video
Shayna Sarosiek, MD discusses WM-NET 1 trial
Deep responses following treatment with Ioncastuximab tesirine (WM-NET1 trial) in patients with Relapsed/Refractory including those with high risk, TP53-altered Waldenstrom macroglobulinemia.
Video
Jacqueline Garcia, MD discussed results from the Phase # VERONA study
Subgroup analyses from the randomized, Phase 3 VERONA study of venetoclax with azacitidine (Ven+Aza) versus placebo with azacititine (Pbo+Aza) in patients with treatment-naive, intermediate and higher-risk Myelodysplastic Syndromes (HR-MDS)
Video
Reid W. Merryman, MD discusses results of a multicenter phase II trial
Rituximab and epcoritamab as first-line therapy for patients with high-tumor burden follicular lymphoma
Video
Andrew A. Lane, MD, PhD discuss results from a phase 2 Study
Tagraxofusp, azacitidine, and venetoclax (TAG-AZA-VEN) triplet therapy shows efficacy, tolerability, and transplant potential in patients with blastic plasmacytoid dendtritic cell neoplasm (BPDCN)